WNT signaling in bone homeostasis and disease: from human mutations to treatments (original) (raw)

• Nüsslein-Volhard, C. & Wieschaus, E. Mutations affecting segment number and polarity in Drosophila. Nature 287, 795–801 (1980).
  PubMed Google Scholar
• Cabrera, C.V., Alonso, M.C., Johnston, P., Phillips, R.G. & Lawrence, P.A. Phenocopies induced with antisense RNA identify the wingless gene. Cell 50, 659–663 (1987).
  CAS PubMed Google Scholar
• Nusse, R. & Varmus, H.E. Many tumors induced by the mouse mammary tumor virus contain a provirus integrated in the same region of the host genome. Cell 31, 99–109 (1982).
  CAS PubMed Google Scholar
• Kinzler, K.W. et al. Identification of a gene located at chromosome 5q21 that is mutated in colorectal cancers. Science 251, 1366–1370 (1991).
  CAS PubMed Google Scholar
• Nishisho, I. et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 253, 665–669 (1991).
  CAS PubMed Google Scholar
• Gong, Y. et al. Osteoporosis-Pseudoglioma Syndrome Collaborative Group. LDL receptor–related protein 5 (LRP5) affects bone accrual and eye development. Cell 107, 513–523 (2001).
  CAS PubMed Google Scholar
• Little, R.D. et al. A mutation in the LDL receptor–related protein 5 gene results in the autosomal dominant high–bone-mass trait. Am. J. Hum. Genet. 70, 11–19 (2002).
  CAS PubMed Google Scholar
• Boyden, L.M. et al. High bone density due to a mutation in LDL-receptor–related protein 5. N. Engl. J. Med. 346, 1513–1521 (2002).
  CAS PubMed Google Scholar
• Poole, K.E. et al. Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. FASEB J. 19, 1842–1844 (2005).
  CAS PubMed Google Scholar
• van Bezooijen, R.L. et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J. Exp. Med. 199, 805–814 (2004).
  CAS PubMed PubMed Central Google Scholar
• Brunkow, M.E. et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am. J. Hum. Genet. 68, 577–589 (2001).
  CAS PubMed PubMed Central Google Scholar
• Balemans, W. et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J. Med. Genet. 39, 91–97 (2002).
  CAS PubMed PubMed Central Google Scholar
• Loots, G.G. et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res. 15, 928–935 (2005).
  CAS PubMed PubMed Central Google Scholar
• Balemans, W. et al. The binding between sclerostin and LRP5 is altered by DKK1 and by high–bone mass LRP5 mutations. Calcif. Tissue Int. 82, 445–453 (2008).
  CAS PubMed Google Scholar
• Ellies, D.L. et al. Bone density ligand, Sclerostin, directly interacts with LRP5 but not LRP5G171V to modulate Wnt activity. J. Bone Miner. Res. 21, 1738–1749 (2006).
  CAS PubMed Google Scholar
• Ai, M., Holmen, S.L., Van Hul, W., Williams, B.O. & Warman, M.L. Reduced affinity to and inhibition by DKK1 form a common mechanism by which high bone mass–associated missense mutations in LRP5 affect canonical Wnt signaling. Mol. Cell. Biol. 25, 4946–4955 (2005).
  CAS PubMed PubMed Central Google Scholar
• Cadigan, K.M. & Peifer, M. Wnt signaling from development to disease: insights from model systems. Cold Spring Harb. Perspect. Biol. 1, a002881 (2009).
  PubMed PubMed Central Google Scholar
• Jenny, A. Planar cell polarity signaling in the Drosophila eye. Curr. Top. Dev. Biol. 93, 189–227 (2010).
  PubMed PubMed Central Google Scholar
• Kohn, A.D. & Moon, R.T. Wnt and calcium signaling: β-catenin–independent pathways. Cell Calcium 38, 439–446 (2005).
  CAS PubMed Google Scholar
• van Amerongen, R. & Nusse, R. Towards an integrated view of Wnt signaling in development. Development 136, 3205–3214 (2009).
  CAS PubMed Google Scholar
• Kikuchi, A., Yamamoto, H. & Sato, A. Selective activation mechanisms of Wnt signaling pathways. Trends Cell Biol. 19, 119–129 (2009).
  CAS PubMed Google Scholar
• Liu, Y. et al. The orphan receptor tyrosine kinase Ror2 promotes osteoblast differentiation and enhances ex vivo bone formation. Mol. Endocrinol. 21, 376–387 (2007).
  CAS PubMed Google Scholar
• Long, F. Building strong bones: molecular regulation of the osteoblast lineage. Nat. Rev. Mol. Cell Biol. 13, 27–38 (2012).
  CAS Google Scholar
• Bianco, P. Minireview: the stem cell next door: skeletal and hematopoietic stem cell “niches” in bone. Endocrinology 152, 2957–2962 (2011).
  CAS PubMed Google Scholar
• Confavreux, C.B., Levine, R.L. & Karsenty, G. A paradigm of integrative physiology, the crosstalk between bone and energy metabolisms. Mol. Cell. Endocrinol. 310, 21–29 (2009).
  CAS PubMed PubMed Central Google Scholar
• Oury, F. et al. Endocrine regulation of male fertility by the skeleton. Cell 144, 796–809 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kennell, J.A. & MacDougald, O.A. Wnt signaling inhibits adipogenesis through β-catenin–dependent and –independent mechansims. J. Biol. Chem. 280, 24004–24010 (2005).
  CAS PubMed Google Scholar
• Day, T.F., Guo, X., Garrett-Beal, L. & Yang, Y. Wnt/β-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev. Cell 8, 739–750 (2005).
  CAS PubMed Google Scholar
• Hill, T.P., Später, D., Taketo, M.M., Birchmeier, W. & Hartmann, C. Canonical Wnt/β-catenin signaling prevents osteoblasts from differentiating into chondrocytes. Dev. Cell 8, 727–738 (2005).
  CAS PubMed Google Scholar
• Hu, H. et al. Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development 132, 49–60 (2005).
  CAS PubMed Google Scholar
• Kato, M. et al. Cbfa1-independent decrease in osteoblast proliferation, osteopenia, and persistent embryonic eye vascularization in mice deficient in Lrp5, a Wnt coreceptor. J. Cell Biol. 157, 303–314 (2002).
  CAS PubMed PubMed Central Google Scholar
• Bennett, C.N. et al. Wnt10b increases postnatal bone formation by enhancing osteoblast differentiation. J. Bone Miner. Res. 22, 1924–1932 (2007).
  CAS PubMed Google Scholar
• Miclea, R.L. et al. Adenomatous polyposis coli-mediated control of β-catenin is essential for both chondrogenic and osteogenic differentiation of skeletal precursors. BMC Dev. Biol. 9, 26 (2009).
  PubMed PubMed Central Google Scholar
• Glass, D.A. II et al. Canonical Wnt signaling in differentiated osteoblasts controls osteoclast differentiation. Dev. Cell 8, 751–764 (2005).
  CAS PubMed Google Scholar
• Holmen, S.L. et al. Essential role of β-catenin in postnatal bone acquisition. J. Biol. Chem. 280, 21162–21168 (2005).
  CAS PubMed Google Scholar
• Kramer, I. et al. Osteocyte Wnt/β-catenin signaling is required for normal bone homeostasis. Mol. Cell. Biol. 30, 3071–3085 (2010).
  CAS PubMed PubMed Central Google Scholar
• Pederson, L., Ruan, M., Westendorf, J.J., Khosla, S. & Oursler, M.J. Regulation of bone formation by osteoclasts involves Wnt/BMP signaling and the chemokine sphingosine-1-phosphate. Proc. Natl. Acad. Sci. USA 105, 20764–20769 (2008).
  CAS PubMed PubMed Central Google Scholar
• Wei, W. et al. Biphasic and dosage-dependent regulation of osteoclastogenesis by β-catenin. Mol. Cell. Biol. 31, 4706–4719 (2011).
  CAS Google Scholar
• Santiago, F., Oguma, J., Brown, A.M. & Laurence, J. Noncanonical Wnt signaling promotes osteoclast differentiation and is facilitated by the human immunodeficiency virus protease inhibitor ritonavir. Biochem. Biophys. Res. Commun. 417, 223–230 (2012).
  CAS PubMed Google Scholar
• Maeda, K. et al. Wnt5a-Ror2 signaling between osteoblast-lineage cells and osteoclast precursors enhances osteoclastogenesis. Nat. Med. 18, 405–412 (2012).
  CAS PubMed Google Scholar
• Terauchi, M. et al. T lymphocytes amplify the anabolic activity of parathyroid hormone through Wnt10b signaling. Cell Metab. 10, 229–240 (2009).
  CAS PubMed PubMed Central Google Scholar
• Bennett, C.N. et al. Regulation of osteoblastogenesis and bone mass by Wnt10b. Proc. Natl. Acad. Sci. USA 102, 3324–3329 (2005).
  CAS PubMed PubMed Central Google Scholar
• Stevens, J.R. et al. Wnt10b deficiency results in age-dependent loss of bone mass and progressive reduction of mesenchymal progenitor cells. J. Bone Miner. Res. 25, 2138–2147 (2010).
  CAS PubMed PubMed Central Google Scholar
• Fleming, H.E. et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. Cell Stem Cell 2, 274–283 (2008).
  CAS PubMed PubMed Central Google Scholar
• Schaniel, C. et al. Wnt-inhibitory factor 1 dysregulation of the bone marrow niche exhausts hematopoietic stem cells. Blood 118, 2420–2429 (2011).
  CAS PubMed PubMed Central Google Scholar
• Renström, J. et al. Secreted frizzled-related protein 1 extrinsically regulates cycling activity and maintenance of hematopoietic stem cells. Cell Stem Cell 5, 157–167 (2009).
  PubMed Google Scholar
• Calvi, L.M. et al. Osteoblastic cells regulate the haematopoietic stem cell niche. Nature 425, 841–846 (2003).
  CAS PubMed Google Scholar
• Rodda, S.J. & McMahon, A.P. Distinct roles for Hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors. Development 133, 3231–3244 (2006).
  CAS PubMed Google Scholar
• Zhong, Z. et al. Wntless functions in mature osteoblasts to regulate bone mass. Proc. Natl. Acad. Sci. USA 109, E2197–E2204 (2012).
  CAS PubMed PubMed Central Google Scholar
• Nam, J.S., Turcotte, T.J., Smith, P.F., Choi, S. & Yoon, J.K. Mouse cristin/R-spondin family proteins are novel ligands for the Frizzled 8 and LRP6 receptors and activate β-catenin–dependent gene expression. J. Biol. Chem. 281, 13247–13257 (2006).
  CAS PubMed Google Scholar
• Binnerts, M.E. et al. R Spondin1 regulates Wnt signaling by inhibiting internalization of LRP6. Proc. Natl. Acad. Sci. USA 104, 14700–14705 (2007).
  CAS PubMed PubMed Central Google Scholar
• Carmon, K.S., Gong, X., Lin, Q., Thomas, A. & Liu, Q. R-spondins function as ligands of the orphan receptors LGR4 and LGR5 to regulate Wnt/β-catenin signaling. Proc. Natl. Acad. Sci. USA 108, 11452–11457 (2011).
  CAS PubMed PubMed Central Google Scholar
• de Lau, W. et al. Lgr5 homologues associate with Wnt receptors and mediate R-spondin signalling. Nature 476, 293–297 (2011).
  CAS PubMed Google Scholar
• Luo, J. et al. Regulation of bone formation and remodeling by G-protein–coupled receptor 48. Development 136, 2747–2756 (2009).
  CAS PubMed PubMed Central Google Scholar
• Jin, Y.R., Turcotte, T.J., Crocker, A.L., Han, X.H. & Yoon, J.K. The canonical Wnt signaling activator, R-spondin2, regulates craniofacial patterning and morphogenesis within the branchial arch through ectodermal-mesenchymal interaction. Dev. Biol. 352, 1–13 (2011).
  CAS PubMed PubMed Central Google Scholar
• Friedman, M.S., Oyserman, S.M. & Hankenson, K.D. Wnt11 promotes osteoblast maturation and mineralization through R-spondin 2. J. Biol. Chem. 284, 14117–14125 (2009).
  CAS PubMed PubMed Central Google Scholar
• Lu, W. et al. R-spondin1 synergizes with Wnt3A in inducing osteoblast differentiation and osteoprotegerin expression. FEBS Lett. 582, 643–650 (2008).
  CAS PubMed Google Scholar
• Smallwood, P.M., Williams, J., Xu, Q., Leahy, D.J. & Nathans, J. Mutational analysis of Norrin-Frizzled4 recognition. J. Biol. Chem. 282, 4057–4068 (2007).
  CAS PubMed Google Scholar
• Ai, M., Heeger, S., Bartels, C.F. & Schelling, D.K. Osteoporosis-Pseudoglioma Collaborative Group. Clinical and molecular findings in osteoporosis-pseudoglioma syndrome. Am. J. Hum. Genet. 77, 741–753 (2005).
  CAS PubMed PubMed Central Google Scholar
• He, X., Semenov, M., Tamai, K. & Zeng, X. LDL receptor-related proteins 5 and 6 in Wnt/β-catenin signaling: arrows point the way. Development 131, 1663–1677 (2004).
  CAS PubMed Google Scholar
• Clément-Lacroix, P. et al. Lrp5-independent activation of Wnt signaling by lithium chloride increases bone formation and bone mass in mice. Proc. Natl. Acad. Sci. USA 102, 17406–17411 (2005).
  PubMed PubMed Central Google Scholar
• Cui, Y. et al. Lrp5 functions in bone to regulate bone mass. Nat. Med. 17, 684–691 (2011).
  CAS PubMed PubMed Central Google Scholar
• Babij, P. et al. High bone mass in mice expressing a mutant LRP5 gene. J. Bone Miner. Res. 18, 960–974 (2003).
  CAS PubMed Google Scholar
• Yadav, V.K. et al. Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135, 825–837 (2008).
  CAS PubMed PubMed Central Google Scholar
• Holmen, S.L. et al. Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6. J. Bone Miner. Res. 19, 2033–2040 (2004).
  CAS PubMed Google Scholar
• Kubota, T. et al. Lrp6 hypomorphic mutation affects bone mass through bone resorption in mice and impairs interaction with Mesd. J. Bone Miner. Res. 23, 1661–1671 (2008).
  CAS PubMed Google Scholar
• Joeng, K.S., Schumacher, C.A., Zylstra-Diegel, C.R., Long, F. & Williams, B.O. Lrp5 and Lrp6 redundantly control skeletal development in the mouse embryo. Dev. Biol. 359, 222–229 (2011).
  CAS PubMed PubMed Central Google Scholar
• Winkler, D.G. et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 22, 6267–6276 (2003).
  CAS PubMed PubMed Central Google Scholar
• Lin, C. et al. Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/β-catenin signaling. J. Bone Miner. Res. 24, 1651–1661 (2009).
  CAS PubMed Google Scholar
• Morvan, F. et al. Deletion of a single allele of the Dkk1 gene leads to an increase in bone formation and bone mass. J. Bone Miner. Res. 21, 934–945 (2006).
  CAS PubMed Google Scholar
• Li, J. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone 39, 754–766 (2006).
  CAS PubMed Google Scholar
• Li, X. et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J. Bone Miner. Res. 23, 860–869 (2008).
  PubMed Google Scholar
• Yan, Y. et al. Axin2 controls bone remodeling through the β-catenin–BMP signaling pathway in adult mice. J. Cell Sci. 122, 3566–3578 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kugimiya, F. et al. GSK-3β controls osteogenesis through regulating Runx2 activity. PLoS ONE 2, e837 (2007).
  PubMed PubMed Central Google Scholar
• Hoeppner, L.H., Secreto, F.J., Razidlo, D.F., Whitney, T.J. & Westendorf, J.J. Lef1ΔN binds β-catenin and increases osteoblast activity and trabecular bone mass. J. Biol. Chem. 286, 10950–10959 (2011).
  CAS PubMed PubMed Central Google Scholar
• Di Benedetto, A. et al. N-cadherin and cadherin 11 modulate postnatal bone growth and osteoblast differentiation by distinct mechanisms. J. Cell Sci. 123, 2640–2648 (2010).
  CAS PubMed PubMed Central Google Scholar
• Almeida, M., Han, L., Martin-Millan, M., O′Brien, C.A. & Manolagas, S.C. Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting β-catenin from T cell factor– to forkhead box O–mediated transcription. J. Biol. Chem. 282, 27298–27305 (2007).
  CAS PubMed Google Scholar
• Ahn, Y., Sanderson, B.W., Klein, O.D. & Krumlauf, R. Inhibition of Wnt signaling by Wise (Sostdc1) and negative feedback from Shh controls tooth number and patterning. Development 137, 3221–3231 (2010).
  CAS PubMed PubMed Central Google Scholar
• Veverka, V. et al. Characterization of the structural features and interactions of sclerostin: molecular insight into a key regulator of Wnt-mediated bone formation. J. Biol. Chem. 284, 10890–10900 (2009).
  CAS PubMed PubMed Central Google Scholar
• Weidauer, S.E. et al. NMR structure of the Wnt modulator protein Sclerostin. Biochem. Biophys. Res. Commun. 380, 160–165 (2009).
  CAS PubMed Google Scholar
• Hens, J.R. et al. TOPGAL mice show that the canonical Wnt signaling pathway is active during bone development and growth and is activated by mechanical loading in vitro. J. Bone Miner. Res. 20, 1103–1113 (2005).
  CAS PubMed Google Scholar
• Li, X. et al. Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J. Biol. Chem. 280, 19883–19887 (2005).
  CAS PubMed Google Scholar
• Semënov, M., Tamai, K. & He, X. SOST is a ligand for LRP5/LRP6 and a Wnt signaling inhibitor. J. Biol. Chem. 280, 26770–26775 (2005).
  PubMed Google Scholar
• Bourhis, E. et al. Wnt antagonists bind through a short peptide to the first β-propeller domain of LRP5/6. Structure 19, 1433–1442 (2011).
  CAS PubMed Google Scholar
• Pangrazio, A. et al. Identification of the first deletion in the LRP5 gene in a patient with autosomal dominant osteopetrosis type I. Bone 49, 568–571 (2011).
  CAS PubMed PubMed Central Google Scholar
• Krause, C. et al. Distinct modes of inhibition by sclerostin on bone morphogenetic protein and Wnt signaling pathways. J. Biol. Chem. 285, 41614–41626 (2010).
  CAS PubMed PubMed Central Google Scholar
• Leupin, O. et al. Bone overgrowth-associated mutations in the LRP4 gene impair Sclerostin facilitator function. J. Biol. Chem. 286, 19489–19500 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bourhis, E. et al. Reconstitution of a frizzled8.Wnt3a.LRP6 signaling complex reveals multiple Wnt and Dkk1 binding sites on LRP6. J. Biol. Chem. 285, 9172–9179 (2010).
  CAS PubMed PubMed Central Google Scholar
• Semënov, M.V., Zhang, X. & He, X. DKK1 antagonizes Wnt signaling without promotion of LRP6 internalization and degradation. J. Biol. Chem. 283, 21427–21432 (2008).
  PubMed PubMed Central Google Scholar
• Li, X. et al. Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. J. Bone Miner. Res. 26, 2610–2621 (2011).
  CAS PubMed Google Scholar
• Wang, F.S. et al. Knocking down dickkopf-1 alleviates estrogen deficiency induction of bone loss. A histomorphological study in ovariectomized rats. Bone 40, 485–492 (2007).
  CAS PubMed Google Scholar
• Tian, X., Jee, W.S., Li, X., Paszty, C. & Ke, H.Z. Sclerostin antibody increases bone mass by stimulating bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 48, 197–201 (2011).
  CAS PubMed Google Scholar
• Schulze, J. et al. Negative regulation of bone formation by the transmembrane Wnt antagonist Kremen-2. PLoS ONE 5, e10309 (2010).
  PubMed PubMed Central Google Scholar
• Choi, H.Y., Dieckmann, M., Herz, J. & Niemeier, A. Lrp4, a novel receptor for Dickkopf 1 and sclerostin, is expressed by osteoblasts and regulates bone growth and turnover in vivo. PLoS ONE 4, e7930 (2009).
  PubMed PubMed Central Google Scholar
• Li, X. et al. Dkk2 has a role in terminal osteoblast differentiation and mineralized matrix formation. Nat. Genet. 37, 945–952 (2005).
  CAS PubMed Google Scholar
• Robling, A.G. et al. Mechanical stimulation of bone in vivo reduces osteocyte expression of Sost/sclerostin. J. Biol. Chem. 283, 5866–5875 (2008).
  CAS PubMed Google Scholar
• Bonewald, L.F. & Johnson, M.L. Osteocytes, mechanosensing and Wnt signaling. Bone 42, 606–615 (2008).
  CAS PubMed PubMed Central Google Scholar
• Sabbagh, Y. et al. Repression of osteocyte Wnt/β-catenin signaling is an early event in the progression of renal osteodystrophy. J. Bone Miner. Res. 27, 1757–1772 (2012).
  CAS PubMed Google Scholar
• Turner, C.H. et al. Mechanobiology of the skeleton. Sci. Signal. 2, pt3 (2009).
  PubMed PubMed Central Google Scholar
• Gaudio, A. et al. Increased sclerostin serum levels associated with bone formation and resorption markers in patients with immobilization-induced bone loss. J. Clin. Endocrinol. Metab. 95, 2248–2253 (2010).
  CAS PubMed Google Scholar
• Robinson, J.A. et al. Wnt/β-catenin signaling is a normal physiological response to mechanical loading in bone. J. Biol. Chem. 281, 31720–31728 (2006).
  CAS PubMed Google Scholar
• Sawakami, K. et al. The Wnt co-receptor LRP5 is essential for skeletal mechanotransduction but not for the anabolic bone response to parathyroid hormone treatment. J. Biol. Chem. 281, 23698–23711 (2006).
  CAS PubMed Google Scholar
• Saxon, L.K., Jackson, B.F., Sugiyama, T., Lanyon, L.E. & Price, J.S. Analysis of multiple bone responses to graded strains above functional levels, and to disuse, in mice in vivo show that the human Lrp5 G171V high bone mass mutation increases the osteogenic response to loading but that lack of Lrp5 activity reduces it. Bone 49, 184–193 (2011).
  CAS PubMed PubMed Central Google Scholar
• Nakashima, T. et al. Evidence for osteocyte regulation of bone homeostasis through RANKL expression. Nat. Med. 17, 1231–1234 (2011).
  CAS PubMed Google Scholar
• Xiong, J. et al. Matrix-embedded cells control osteoclast formation. Nat. Med. 17, 1235–1241 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bonewald, L.F. The amazing osteocyte. J. Bone Miner. Res. 26, 229–238 (2011).
  CAS PubMed Google Scholar
• Qin, L., Raggatt, L.J. & Partridge, N.C. Parathyroid hormone: a double-edged sword for bone metabolism. Trends Endocrinol. Metab. 15, 60–65 (2004).
  CAS PubMed Google Scholar
• Keller, H. & Kneissel, M. SOST is a target gene for PTH in bone. Bone 37, 148–158 (2005).
  CAS PubMed Google Scholar
• Bellido, T. et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146, 4577–4583 (2005).
  CAS PubMed Google Scholar
• Li, X. et al. Determination of dual effects of parathyroid hormone on skeletal gene expression in vivo by microarray and network analysis. J. Biol. Chem. 282, 33086–33097 (2007).
  CAS PubMed Google Scholar
• Guo, J. et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 11, 161–171 (2010).
  CAS PubMed PubMed Central Google Scholar
• Costa, A.G. et al. Circulating Sclerostin in disorders of parathyroid gland function. J. Clin. Endocrinol. Metab. 96, 3804–3810 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kaji, H., Imanishi, Y., Sugimoto, T. & Seino, S. Comparisons of serum sclerostin levels among patients with postmenopausal osteoporosis, primary hyperparathyroidism and osteomalacia. Exp. Clin. Endocrinol. Diabetes 119, 440–444 (2011).
  CAS PubMed Google Scholar
• van Lierop, A.H., Witteveen, J.E., Hamdy, N.A. & Papapoulos, S.E. Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls. Eur. J. Endocrinol. 163, 833–837 (2010).
  CAS PubMed Google Scholar
• Drake, M.T. et al. Effects of parathyroid hormone treatment on circulating sclerostin levels in postmenopausal women. J. Clin. Endocrinol. Metab. 95, 5056–5062 (2010).
  CAS PubMed PubMed Central Google Scholar
• Kramer, I., Loots, G.G., Studer, A., Keller, H. & Kneissel, M. Parathyroid hormone (PTH)-induced bone gain is blunted in SOST overexpressing and deficient mice. J. Bone Miner. Res. 25, 178–189 (2010).
  CAS PubMed Google Scholar
• Robling, A.G. et al. Anabolic and catabolic regimens of human parathyroid hormone 1–34 elicit bone- and envelope-specific attenuation of skeletal effects in Sost-deficient mice. Endocrinology 152, 2963–2975 (2011).
  CAS PubMed PubMed Central Google Scholar
• Rhee, Y. et al. PTH receptor signaling in osteocytes governs periosteal bone formation and intracortical remodeling. J. Bone Miner. Res. 26, 1035–1046 (2011).
  CAS PubMed Google Scholar
• Bodine, P.V., Seestaller-Wehr, L., Kharode, Y.P., Bex, F.J. & Komm, B.S. Bone anabolic effects of parathyroid hormone are blunted by deletion of the Wnt antagonist secreted frizzled-related protein-1. J. Cell. Physiol. 210, 352–357 (2007).
  CAS PubMed Google Scholar
• Yao, W. et al. Overexpression of secreted frizzled-related protein 1 inhibits bone formation and attenuates parathyroid hormone bone anabolic effects. J. Bone Miner. Res. 25, 190–199 (2010).
  CAS PubMed Google Scholar
• O′Brien, C.A. et al. Control of bone mass and remodeling by PTH receptor signaling in osteocytes. PLoS ONE 3, e2942 (2008).
  PubMed PubMed Central Google Scholar
• Powell, W.F. Jr. et al. Targeted ablation of the PTH/PTHrP receptor in osteocytes impairs bone structure and homeostatic calcemic responses. J. Endocrinol. 209, 21–32 (2011).
  CAS PubMed PubMed Central Google Scholar
• Wan, M. et al. Parathyroid hormone signaling through low-density lipoprotein–related protein 6. Genes Dev. 22, 2968–2979 (2008).
  CAS PubMed PubMed Central Google Scholar
• Wu, J.Y. et al. Gsα enhances commitment of mesenchymal progenitors to the osteoblast lineage but restrains osteoblast differentiation in mice. J. Clin. Invest. 121, 3492–3504 (2011).
  CAS PubMed PubMed Central Google Scholar
• Sieber, C., Kopf, J., Hiepen, C. & Knaus, P. Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev. 20, 343–355 (2009).
  CAS PubMed Google Scholar
• Guo, X. & Wang, X.F. Signaling cross-talk between TGF-β/BMP and other pathways. Cell Res. 19, 71–88 (2009).
  CAS PubMed Google Scholar
• Lin, G.L. & Hankenson, K.D. Integration of BMP, Wnt, and Notch signaling pathways in osteoblast differentiation. J. Cell. Biochem. 112, 3491–3501 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kamiya, N. The role of BMPs in bone anabolism and their potential targets SOST and DKK1. Curr. Mol. Pharmacol. 5, 153–163 (2012).
  CAS PubMed Google Scholar
• Bain, G., Müller, T., Wang, X. & Papkoff, J. Activated β-catenin induces osteoblast differentiation of C3H10T1/2 cells and participates in BMP2 mediated signal transduction. Biochem. Biophys. Res. Commun. 301, 84–91 (2003).
  CAS PubMed Google Scholar
• Lintern, K.B., Guidato, S., Rowe, A., Saldanha, J.W. & Itasaki, N. Characterization of wise protein and its molecular mechanism to interact with both Wnt and BMP signals. J. Biol. Chem. 284, 23159–23168 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kamiya, N., Kaartinen, V.M. & Mishina, Y. Loss-of-function of ACVR1 in osteoblasts increases bone mass and activates canonical Wnt signaling through suppression of Wnt inhibitors SOST and DKK1. Biochem. Biophys. Res. Commun. 414, 326–330 (2011).
  CAS PubMed PubMed Central Google Scholar
• Kaplan, F.S. et al. Investigations of activated ACVR1/ALK2, a bone morphogenetic protein type I receptor, that causes fibrodysplasia ossificans progressiva. Methods Enzymol. 484, 357–373 (2010).
  CAS PubMed PubMed Central Google Scholar
• Baud′huin, M. et al. A soluble bone morphogenetic protein type IA receptor increases bone mass and bone strength. Proc. Natl. Acad. Sci. USA 109, 12207–12212 (2012).
  PubMed PubMed Central Google Scholar
• Canalis, E., Brunet, L.J., Parker, K. & Zanotti, S. Conditional inactivation of noggin in the postnatal skeleton causes osteopenia. Endocrinology 153, 1616–1626 (2012).
  CAS PubMed PubMed Central Google Scholar
• Mbalaviele, G., Shin, C.S. & Civitelli, R. Cell-cell adhesion and signaling through cadherins: connecting bone cells in their microenvironment. J. Bone Miner. Res. 21, 1821–1827 (2006).
  CAS PubMed Google Scholar
• Haÿ, E. et al. N-cadherin interacts with axin and LRP5 to negatively regulate Wnt/β-catenin signaling, osteoblast function, and bone formation. Mol. Cell. Biol. 29, 953–964 (2009).
  PubMed Google Scholar
• Barros, E.R., Dias da Silva, M.R., Kunii, I.S. & Lazaretti-Castro, M. Three years follow-up of pamidronate therapy in two brothers with osteoporosis-pseudoglioma syndrome (OPPG) carrying an LRP5 mutation. J. Pediatr. Endocrinol. Metab. 21, 811–818 (2008).
  PubMed Google Scholar
• Cheung, W.M. et al. A family with osteoporosis pseudoglioma syndrome due to compound heterozygosity of two novel mutations in the LRP5 gene. Bone 39, 470–476 (2006).
  CAS PubMed Google Scholar
• Laine, C.M. et al. Novel mutations affecting LRP5 splicing in patients with osteoporosis-pseudoglioma syndrome (OPPG). Eur. J. Hum. Genet. 19, 875–881 (2011).
  CAS PubMed PubMed Central Google Scholar
• Streeten, E.A. et al. Osteoporosis-pseudoglioma syndrome: description of 9 new cases and beneficial response to bisphosphonates. Bone 43, 584–590 (2008).
  CAS PubMed PubMed Central Google Scholar
• Korvala, J. et al. Mutations in LRP5 cause primary osteoporosis without features of OI by reducing Wnt signaling activity. BMC Med. Genet. 13, 26 (2012).
  CAS PubMed PubMed Central Google Scholar
• Rickels, M.R., Zhang, X., Mumm, S. & Whyte, M.P. Oropharyngeal skeletal disease accompanying high bone mass and novel LRP5 mutation. J. Bone Miner. Res. 20, 878–885 (2005).
  CAS PubMed Google Scholar
• Van Wesenbeeck, L. et al. Six novel missense mutations in the LDL receptor–related protein 5 (LRP5) gene in different conditions with an increased bone density. Am. J. Hum. Genet. 72, 763–771 (2003).
  CAS PubMed PubMed Central Google Scholar
• Mani, A. et al. LRP6 mutation in a family with early coronary disease and metabolic risk factors. Science 315, 1278–1282 (2007).
  CAS PubMed PubMed Central Google Scholar
• Kim, S.J. et al. Identification of signal peptide domain SOST mutations in autosomal dominant craniodiaphyseal dysplasia. Hum. Genet. 129, 497–502 (2011).
  CAS PubMed Google Scholar
• van Lierop, A.H. et al. Patients with sclerosteosis and disease carriers: human models of the effect of sclerostin on bone turnover. J. Bone Miner. Res. 26, 2804–2811 (2011).
  CAS PubMed Google Scholar
• Hall, C.L., Kang, S., MacDougald, O.A. & Keller, E.T. Role of Wnts in prostate cancer bone metastases. J. Cell. Biochem. 97, 661–672 (2006).
  CAS PubMed Google Scholar
• Pinzone, J.J. et al. The role of Dickkopf-1 in bone development, homeostasis, and disease. Blood 113, 517–525 (2009).
  CAS PubMed PubMed Central Google Scholar
• Kansara, M. et al. Wnt inhibitory factor 1 is epigenetically silenced in human osteosarcoma, and targeted disruption accelerates osteosarcomagenesis in mice. J. Clin. Invest. 119, 837–851 (2009).
  CAS PubMed PubMed Central Google Scholar
• Perdu, B. et al. Osteopathia striata with cranial sclerosis owing to WTX gene defect. J. Bone Miner. Res. 25, 82–90 (2010).
  CAS PubMed Google Scholar
• Moisan, A. et al. The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev. Cell 20, 583–596 (2011).
  CAS PubMed PubMed Central Google Scholar
• Sims, A.M. et al. Genetic analyses in a sample of individuals with high or low BMD shows association with multiple Wnt pathway genes. J. Bone Miner. Res. 23, 499–506 (2008).
  CAS PubMed Google Scholar
• van Meurs, J.B. et al. GENOMOS Study. Large-scale analysis of association between LRP5 and LRP6 variants and osteoporosis. J. Am. Med. Assoc. 299, 1277–1290 (2008).
  CAS Google Scholar
• Estrada, K. et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat. Genet. 44, 491–501 (2012).
  CAS PubMed PubMed Central Google Scholar
• Li, W.F. et al. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum. Genet. 127, 249–285 (2010).
  CAS PubMed Google Scholar
• Richards, J.B. et al. Bone mineral density, osteoporosis, and osteoporotic fractures: a genome-wide association study. Lancet 371, 1505–1512 (2008).
  CAS PubMed PubMed Central Google Scholar
• Rivadeneira, F. et al. Twenty bone-mineral-density loci identified by large-scale meta-analysis of genome-wide association studies. Nat. Genet. 41, 1199–1206 (2009).
  CAS PubMed PubMed Central Google Scholar
• Styrkarsdottir, U. et al. Multiple genetic loci for bone mineral density and fractures. N. Engl. J. Med. 358, 2355–2365 (2008).
  CAS PubMed Google Scholar
• Styrkarsdottir, U. et al. New sequence variants associated with bone mineral density. Nat. Genet. 41, 15–17 (2009).
  CAS PubMed Google Scholar
• Huang, Q.Y., Li, G.H. & Kung, A.W. The –9247 T/C polymorphism in the SOST upstream regulatory region that potentially affects C/EBPα and FOXA1 binding is associated with osteoporosis. Bone 45, 289–294 (2009).
  CAS PubMed Google Scholar
• Yerges, L.M. et al. High-density association study of 383 candidate genes for volumetric BMD at the femoral neck and lumbar spine among older men. J. Bone Miner. Res. 24, 2039–2049 (2009).
  CAS PubMed PubMed Central Google Scholar
• Leupin, O. et al. Control of the SOST bone enhancer by PTH using MEF2 transcription factors. J. Bone Miner. Res. 22, 1957–1967 (2007).
  CAS PubMed Google Scholar
• Miller, P.D. & Derman, R.J. What is the best balance of benefits and risks among anti-resorptive therapies for postmenopausal osteoporosis? Osteoporos. Int. 21, 1793–1802 (2010).
  CAS PubMed Google Scholar
• Baron, R., Ferrari, S. & Russell, R.G. Denosumab and bisphosphonates: different mechanisms of action and effects. Bone 48, 677–692 (2011).
  CAS PubMed Google Scholar
• Rubin, M.R. & Bilezikian, J.P. Parathyroid hormone as an anabolic skeletal therapy. Drugs 65, 2481–2498 (2005).
  CAS PubMed Google Scholar
• Hodsman, A.B. et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. Endocr. Rev. 26, 688–703 (2005).
  CAS PubMed Google Scholar
• McClung, M.R. et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch. Intern. Med. 165, 1762–1768 (2005).
  CAS PubMed Google Scholar
• Paszty, C., Turner, C.H. & Robinson, M.K. Sclerostin: a gem from the genome leads to bone-building antibodies. J. Bone Miner. Res. 25, 1897–1904 (2010).
  CAS PubMed Google Scholar
• Padhi, D., Jang, G., Stouch, B., Fang, L. & Posvar, E. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J. Bone Miner. Res. 26, 19–26 (2011).
  CAS PubMed Google Scholar
• Kramer, I., Keller, H., Leupin, O. & Kneissel, M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol. Metab. 21, 237–244 (2010).
  CAS PubMed Google Scholar
• Fox, J. et al. Effects of daily treatment with parathyroid hormone 1–84 for 16 months on density, architecture and biomechanical properties of cortical bone in adult ovariectomized rhesus monkeys. Bone 41, 321–330 (2007).
  CAS PubMed Google Scholar
• Lindsay, R. et al. Effects of a one-month treatment with PTH(1–34) on bone formation on cancellous, endocortical, and periosteal surfaces of the human ilium. J. Bone Miner. Res. 22, 495–502 (2007).
  CAS PubMed Google Scholar
• Li, X. et al. Sclerostin antibody treatment increases bone formation, bone mass, and bone strength in a rat model of postmenopausal osteoporosis. J. Bone Miner. Res. 24, 578–588 (2009).
  CAS PubMed Google Scholar
• Ominsky, M.S. et al. Two doses of sclerostin antibody in cynomolgus monkeys increases bone formation, bone mineral density, and bone strength. J. Bone Miner. Res. 25, 948–959 (2010).
  CAS PubMed Google Scholar
• Crabtree, N. et al. Intracapsular hip fracture and the region-specific loss of cortical bone: analysis by peripheral quantitative computed tomography. J. Bone Miner. Res. 16, 1318–1328 (2001).
  CAS PubMed Google Scholar
• Epstein, S. Is cortical bone hip? What determines cortical bone properties? Bone 41 (suppl. 1), S3–S8 (2007).
  PubMed Google Scholar
• Zebaze, R.M. et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet 375, 1729–1736 (2010).
  PubMed Google Scholar
• Glantschnig, H. et al. A rate-limiting role for dickkopf-1 in bone formation and the remediation of bone loss in mouse and primate models of postmenopausal osteoporosis by an experimental therapeutic antibody. J. Pharmacol. Exp. Ther. 338, 568–578 (2011).
  CAS PubMed Google Scholar
• Fulciniti, M. et al. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood 114, 371–379 (2009).
  CAS PubMed PubMed Central Google Scholar
• Heath, D.J. et al. Inhibiting Dickkopf-1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma. J. Bone Miner. Res. 24, 425–436 (2009).
  CAS PubMed Google Scholar
• Sieper, J. Spondyloarthropathies in 2010: new insights into therapy—TNF blockade and beyond. Nat. Rev. Rheumatol. 7, 78–80 (2011).
  CAS PubMed Google Scholar
• Diarra, D. et al. Dickkopf-1 is a master regulator of joint remodeling. Nat. Med. 13, 156–163 (2007).
  CAS PubMed Google Scholar
• Krönke, G. et al. R-spondin 1 protects against inflammatory bone damage during murine arthritis by modulating the Wnt pathway. Arthritis Rheum. 62, 2303–2312 (2010).
  PubMed Google Scholar
• Uderhardt, S. et al. Blockade of Dickkopf (DKK)-1 induces fusion of sacroiliac joints. Ann. Rheum. Dis. 69, 592–597 (2010).
  CAS PubMed Google Scholar
• Appel, H. et al. Altered skeletal expression of sclerostin and its link to radiographic progression in ankylosing spondylitis. Arthritis Rheum. 60, 3257–3262 (2009).
  PubMed Google Scholar
• Agholme, F., Li, X., Isaksson, H., Ke, H.Z. & Aspenberg, P. Sclerostin antibody treatment enhances metaphyseal bone healing in rats. J. Bone Miner. Res. 25, 2412–2418 (2010).
  CAS PubMed Google Scholar
• Ominsky, M.S. et al. Inhibition of sclerostin by monoclonal antibody enhances bone healing and improves bone density and strength of nonfractured bones. J. Bone Miner. Res. 26, 1012–1021 (2011).
  CAS PubMed Google Scholar
• Gaur, T. et al. Secreted frizzled related protein 1 is a target to improve fracture healing. J. Cell. Physiol. 220, 174–181 (2009).
  CAS PubMed PubMed Central Google Scholar
• Komatsu, D.E. et al. Modulation of Wnt signaling influences fracture repair. J. Orthop. Res. 28, 928–936 (2010).
  CAS PubMed PubMed Central Google Scholar
• Agholme, F., Isaksson, H., Kuhstoss, S. & Aspenberg, P. The effects of Dickkopf-1 antibody on metaphyseal bone and implant fixation under different loading conditions. Bone 48, 988–996 (2011).
  CAS PubMed Google Scholar
• Sinder, B.P. et al. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J. Bone Miner. Res. 28, 73–80 (2013).
  CAS PubMed Google Scholar
• Bodine, P.V. et al. A small molecule inhibitor of the Wnt antagonist secreted frizzled-related protein-1 stimulates bone formation. Bone 44, 1063–1068 (2009).
  CAS PubMed Google Scholar
• Moore, W.J. et al. Modulation of Wnt signaling through inhibition of secreted frizzled-related protein I (sFRP-1) with N-substituted piperidinyl diphenylsulfonyl sulfonamides: part II. Bioorg. Med. Chem. 18, 190–201 (2010).
  CAS PubMed Google Scholar
• Shi, M. et al. Identification of iminooxothiazolidines as secreted frizzled related protein-1 inhibitors. Bioorg. Med. Chem. Lett. 19, 6337–6339 (2009).
  CAS PubMed Google Scholar
• Warden, S.J. et al. Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 46, 985–992 (2010).
  CAS PubMed PubMed Central Google Scholar
• Kulkarni, N.H. et al. Orally bioavailable GSK-3α/β dual inhibitor increases markers of cellular differentiation in vitro and bone mass in vivo. J. Bone Miner. Res. 21, 910–920 (2006).
  CAS PubMed Google Scholar
• Bolton, J.M. et al. Fracture risk from psychotropic medications: a population-based analysis. J. Clin. Psychopharmacol. 28, 384–391 (2008).
  PubMed Google Scholar
• Vestergaard, P., Rejnmark, L. & Mosekilde, L. Reduced relative risk of fractures among users of lithium. Calcif. Tissue Int. 77, 1–8 (2005).
  CAS PubMed Google Scholar
• Borchert, K.M. et al. High-content screening assay for activators of the Wnt/Fzd pathway in primary human cells. Assay Drug Dev. Technol. 3, 133–141 (2005).
  CAS PubMed Google Scholar
• Verkaar, F., van der Stelt, M., Blankesteijn, W.M., van der Doelen, A.A. & Zaman, G.J. Discovery of novel small molecule activators of β-catenin signaling. PLoS ONE 6, e19185 (2011).
  CAS PubMed PubMed Central Google Scholar
• Johnson, E.B., Hammer, R.E. & Herz, J. Abnormal development of the apical ectodermal ridge and polysyndactyly in Megf7-deficient mice. Hum. Mol. Genet. 14, 3523–3538 (2005).
  CAS PubMed Google Scholar
• Collette, N.M., Genetos, D.C., Murugesh, D., Harland, R.M. & Loots, G.G. Genetic evidence that SOST inhibits WNT signaling in the limb. Dev. Biol. 342, 169–179 (2010).
  CAS PubMed PubMed Central Google Scholar
• Niemann, S. et al. Homozygous WNT3 mutation causes tetra-amelia in a large consanguineous family. Am. J. Hum. Genet. 74, 558–563 (2004).
  CAS PubMed PubMed Central Google Scholar
• Woods, C.G. et al. Mutations in WNT7A cause a range of limb malformations, including Fuhrmann syndrome and Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome. Am. J. Hum. Genet. 79, 402–408 (2006).
  CAS PubMed PubMed Central Google Scholar
• Galceran, J., Farinas, I., Depew, M.J., Clevers, H. & Grosschedl, R. Wnt3a−/−-like phenotype and limb deficiency in Lef1−/−Tcf1−/− mice. Genes Dev. 13, 709–717 (1999).
  CAS PubMed PubMed Central Google Scholar
• Parr, B.A. & McMahon, A.P. Dorsalizing signal Wnt-7a required for normal polarity of D-V and A-P axes of mouse limb. Nature 374, 350–353 (1995).
  CAS PubMed Google Scholar
• Guo, X. et al. Wnt/β-catenin signaling is sufficient and necessary for synovial joint formation. Genes Dev. 18, 2404–2417 (2004).
  CAS PubMed PubMed Central Google Scholar
• Hartmann, C. & Tabin, C.J. Wnt-14 plays a pivotal role in inducing synovial joint formation in the developing appendicular skeleton. Cell 104, 341–351 (2001).
  CAS PubMed Google Scholar
• Wang, B., Sinha, T., Jiao, K., Serra, R. & Wang, J. Disruption of PCP signaling causes limb morphogenesis and skeletal defects and may underlie Robinow syndrome and brachydactyly type B. Hum. Mol. Genet. 20, 271–285 (2011).
  CAS PubMed Google Scholar
• Jin, Y.R., Turcotte, T.J., Crocker, A.L., Han, X.H. & Yoon, J.K. The canonical Wnt signaling activator, R-spondin2, regulates craniofacial patterning and morphogenesis within the branchial arch through ectodermal-mesenchymal interaction. Dev. Biol. 352, 1–13 (2011).
  CAS PubMed PubMed Central Google Scholar
• DeChiara, T.M. et al. Ror2, encoding a receptor-like tyrosine kinase, is required for cartilage and growth plate development. Nat. Genet. 24, 271–274 (2000).
  CAS PubMed Google Scholar
• Lyashenko, N. et al. Mice lacking the orphan receptor ror1 have distinct skeletal abnormalities and are growth retarded. Dev. Dyn. 239, 2266–2277 (2010).
  CAS PubMed Google Scholar
• Mikels, A., Minami, Y. & Nusse, R. Ror2 receptor requires tyrosine kinase activity to mediate Wnt5A signaling. J. Biol. Chem. 284, 30167–30176 (2009).
  CAS PubMed PubMed Central Google Scholar
• Witte, F., Chan, D., Economides, A.N., Mundlos, S. & Stricker, S. Receptor tyrosine kinase-like orphan receptor 2 (ROR2) and Indian hedgehog regulate digit outgrowth mediated by the phalanx-forming region. Proc. Natl. Acad. Sci. USA 107, 14211–14216 (2010).
  CAS PubMed PubMed Central Google Scholar
• Tu, X. et al. Noncanonical Wnt signaling through G protein–linked PKCδ activation promotes bone formation. Dev. Cell 12, 113–127 (2007).
  CAS PubMed PubMed Central Google Scholar
• Takada, I. et al. A histone lysine methyltransferase activated by non-canonical Wnt signalling suppresses PPAR-γ transactivation. Nat. Cell Biol. 9, 1273–1285 (2007).
  CAS PubMed Google Scholar
• Albers, J. et al. Control of bone formation by the serptentine receptor Frizzled-9. J. Cell Biol. 192, 1057–1072 (2011).
  CAS PubMed PubMed Central Google Scholar
• Bodine, P.V. et al. The Wnt antagonist secreted frizzled-related protein-1 is a negative regulator of trabecular bone formation in adult mice. Mol. Endocrinol. 18, 1222–1237 (2004).
  CAS PubMed Google Scholar
• Häusler, K.D. et al. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation. J. Bone Miner. Res. 19, 1873–1881 (2004).
  PubMed Google Scholar
• Nakanishi, R. et al. Osteoblast-targeted expression of Sfrp4 in mice results in low bone mass. J. Bone Miner. Res. 23, 271–277 (2008).
  CAS PubMed Google Scholar
• Berndt, T. et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112, 785–794 (2003).
  CAS PubMed PubMed Central Google Scholar
• Cho, H.Y. et al. Transgenic mice overexpressing secreted frizzled-related proteins (sFRP)4 under the control of serum amyloid P promoter exhibit low bone mass but did not result in disturbed phosphate homeostasis. Bone 47, 263–271 (2010).
  CAS PubMed Google Scholar
• Christov, M., Koren, S., Yuan, Q., Baron, R. & Lanske, B. Genetic ablation of sfrp4 in mice does not affect serum phosphate homeostasis. Endocrinology 152, 2031–2036 (2011).
  CAS PubMed PubMed Central Google Scholar
• Morello, R. et al. Brachy-syndactyly caused by loss of Sfrp2 function. J. Cell. Physiol. 217, 127–137 (2008).
  CAS PubMed PubMed Central Google Scholar
• Nakajima, H. et al. Wnt modulators, SFRP-1, and SFRP-2 are expressed in osteoblasts and differentially regulate hematopoietic stem cells. Biochem. Biophys. Res. Commun. 390, 65–70 (2009).
  CAS PubMed Google Scholar
• Cho, S.W. et al. Wnt inhibitory factor (WIF)-1 inhibits osteoblastic differentiation in mouse embryonic mesenchymal cells. Bone 44, 1069–1077 (2009).
  CAS PubMed Google Scholar